Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

40.73 -0.05 (-0.11%)
Streaming Delayed Price Updated: 11:01 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
This Analyst With 82% Accuracy Rate Boosts PT On Booking Holdings; Here Are 5 Stock Picks For Thursday From Benzinga's Most Accurate Analysts ↗
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
News headline image
Castle Biosciences Announces Third Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences: Q2 Earnings Insights ↗
  Castle Biosciences (NASDAQ:CSTL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
From Castle Biosciences, Inc.
Via Business Wire
News headline image
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
News headline image
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences's Return On Capital Employed Overview ↗
According to data from Benzinga Pro, during Q2, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $34.84 million. Despite a 93.31% increase in earnings, the company posted a loss of $1.65... 
Via Benzinga
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Host Investor Day on Sept. 20, 2022
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Reports Second Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
From Castle Biosciences, Inc.
Via Business Wire
News headline image
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday ↗
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
News headline image
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.